Clin2
NCT07538479Possibly a fitRecruiting

Cold Exposure Plus Immunotherapy for Advanced Solid Tumors

Solid TumorsSolid MalignanciesCold ExposureImmunotherapy

Part of Cancer clinical trials.

This study tests whether controlled cold exposure combined with PD-1/PD-L1 immunotherapy (checkpoint inhibitor drugs that boost your immune system) can help fight solid tumors better than immunotherapy alone. The cold exposure is meant to trigger immune responses that may make the immunotherapy work more effectively.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
24 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Age 18–75 years old
  • Confirmed solid tumor cancer (lung, melanoma, kidney, etc.) that your doctor plans to treat with PD-1/PD-L1 immunotherapy
  • Good overall health (ECOG performance status 0–1), able to walk around and do light daily tasks
  • No severe heart, lung, or blood vessel disease; no severe cold-related conditions like Raynaud's syndrome or cold urticaria
  • If previously treated with immunotherapy, at least 4 weeks must have passed since your last dose, and past side effects must have improved
  • Able to tolerate controlled cold exposure and willing to follow study procedures

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06032845Recruiting· Phase 2
Freezing tumors plus immunotherapy for advanced solid tumors

This trial tests if freezing tumor cells (cryoablation) combined with two drugs (tislelizumab and lenvatinib) can help people whose solid tumors have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.

Shanghai, Shanghai Municipality
NCT07594028Not yet recruiting· Phase 1/Phase 2
Cell therapy plus immunotherapy for advanced solid tumors

This trial tests a combination of two cell-based therapies (SCTB41 and SCTB39-1) with or without standard cancer treatments for advanced solid tumors. The goal is to see if this approach helps slow or shrink tumors while being safe enough to use in patients.

NCT06144671Recruiting· Phase 1/Phase 2
Custom immune cell therapy for advanced solid tumors

This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.

Shanghai, Shanghai Municipality
NCT07766317Not yet recruiting· Phase 1/Phase 2
Personal immune cell therapy for advanced solid tumors

This trial tests a treatment that takes immune cells from your tumor, multiplies them in a lab, and gives them back to you to fight the cancer. It is for people with advanced solid tumors who have tried other treatments or cannot have them.

NCT06173219Recruiting· Phase 1/Phase 2
Radiation and immunotherapy for advanced cancer

This trial tests combining two types of radiation therapy with an immunotherapy drug for people with advanced solid tumors that have spread or come back. The goal is to see if this approach can help when standard treatments have stopped working or aren’t an option.

Beijing, Beijing Municipality
NCT07584954Recruiting· Phase 1
Testing a new cancer immunotherapy in advanced solid tumors

This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.

Fuzhou, Fujian

Hear when a new Cold Exposure trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.